Introduction (Covering Core User Needs: Pain Points & Solutions):
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Bifidobacterium Animalis Subsp. Lactis – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bifidobacterium Animalis Subsp. Lactis market, including market size, share, demand, industry development status, and forecasts for the next few years.
For infant formula manufacturers, probiotic supplement brands, and pet food producers, selecting a clinically validated, stable, and functional probiotic strain is essential for product efficacy and consumer trust. Bifidobacterium animalis subsp. lactis is a probiotic belonging to the genus Bifidobacterium. It is a common probiotic in the intestines of humans and animals. It is a strictly anaerobic Gram-positive bacterium with a short rod or bifidobacterial shape. It is widely used in food, supplements and clinical applications because of its benefits to human health, especially digestive function and immune function. B. animalis lactis (formerly B. lactis) is one of the most extensively studied probiotic strains, with demonstrated benefits for gut microbiota modulation, constipation relief, immune enhancement, and improved lactose tolerance. As consumer awareness of gut health rises, regulations on infant formula tighten, and pet humanization trends drive functional pet food demand, B. animalis lactis is transitioning from specialized probiotic to mainstream functional ingredient.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6092089/bifidobacterium-animalis-subsp–lactis
1. Market Sizing & Growth Trajectory (With 2026–2032 Forecasts)
According to QYResearch’s proprietary market data, the global market for Bifidobacterium Animalis Subsp. Lactis was valued at US$905 million in 2025 and is projected to reach US$1,705 million by 2032, growing at a CAGR of 9.6% from 2026 to 2032. This strong growth is driven by three converging factors: (1) increasing demand for functional infant formula, (2) growth of probiotic supplements and functional foods, and (3) expansion of pet probiotics. In 2024, global production was 6,500 tons, with an average price of US$92 per kg.
By source type, breast milk/infant intestinal sources dominate with approximately 60% of market revenue (human-origin, clinical evidence). Intestinal sources of long-lived people account for 20% (longevity-associated strains), and special environmental sources for 20%. By application, food (infant formula, fermented dairy, beverages, snacks) accounts for approximately 50% of market revenue, medicine and health products (dietary supplements) for 30%, clinical auxiliary treatment for 10%, animal feed (pet food) for 8%, and others for 2%.
2. Technology Deep-Drive: Strain Stability, Acid/Bile Resistance, and Viability
Technical nuances often overlooked:
- Gut health probiotic strain characteristics: Gram-positive, anaerobic, rod-shaped. Optimal growth temperature: 37-41°C. pH tolerance: 4.0-8.0. Bile salt tolerance: 0.3-1.0%. Acid resistance (gastric transit): 70-90% survival at pH 2.5-3.5 for 2 hours. Adhesion to intestinal epithelium: high (Caco-2 cell model). Viable count: 10⁹-10¹¹ CFU/g (freeze-dried powder).
- Infant formula probiotic regulatory requirements: GRAS (Generally Recognized as Safe) status (FDA). Qualified Presumption of Safety (QPS) status (EFSA). Strain-level identification (16S rRNA sequencing, whole genome sequencing). Minimum viable count at expiry: 10⁷-10⁸ CFU/g (infant formula). Clinical studies: randomized controlled trials (RCTs) for safety and efficacy.
Recent 6-month advances (October 2025 – March 2026):
- Novonesis (formerly Chr. Hansen) – BB-12 strain (B. animalis lactis). Most documented Bifidobacterium strain (300+ scientific publications). Used in infant formula, supplements. Price US$100-200 per kg.
- IFF (Danisco) – Bi-07 strain. Used in combination with other probiotics. Price US$80-150 per kg.
- Yili Group (China) – domestic B. animalis lactis strain. Used in infant formula (Pro-Kid). Price US$60-100 per kg.
3. Industry Segmentation & Key Players
The Bifidobacterium Animalis Subsp. Lactis market is segmented as below:
By Source Type (Strain Origin):
- Breast Milk/Infant Intestinal Sources – Human-origin, clinically validated. Price: US$80-200 per kg. Largest segment.
- Intestinal Sources of Long-Lived People – Longevity-associated. Price: US$70-180 per kg.
- Special Environmental Sources – Novel strains. Price: US$60-150 per kg.
By Application (End-Use Sector):
- Food (infant formula, fermented dairy, beverages, snacks) – 50% of 2025 revenue.
- Medicine and Health Products (dietary supplements, capsules, sachets, gummies) – 30% of revenue.
- Clinical Auxiliary Treatment (hospital, ICU, antibiotic-associated diarrhea) – 10% of revenue.
- Animal Feed (pet food, pet supplements) – 8% of revenue.
- Other (cosmetics, personal care) – 2%.
Key Players (2026 Market Positioning):
Global Leaders: Novonesis (Denmark, BB-12), IFF (USA, Bi-07), Lallemand (Canada), Probiotical (Italy), Sacco System (Italy), Howaru (USA), Unique Biotech (India), ATCC (USA), DSMZ (Germany), Creative Biolabs (USA).
Chinese Leaders: Yili Group (China), Wecare Probiotics (China), Scitop (China), Glac Biotech (China), Yuansheng Biotechnology (China), BGI (China), Guangdong Yikewei Biotech (China), Tianjin Innoorigin Biological Technology (China), ProbioWay (China), Bio-Growing (China).
独家观察 (Exclusive Insight): The B. animalis lactis market is concentrated with Novonesis (≈25-30% market share, BB-12), IFF (≈15-20%), and Lallemand (≈10-15%) as top players. Novonesis (Chr. Hansen) dominates with BB-12, the most researched Bifidobacterium strain. IFF (Danisco) is #2 with Bi-07. Chinese manufacturers (Yili, Wecare, Scitop, Glac, Yuansheng, BGI, Yikewei, Innoorigin, ProbioWay, Bio-Growing) dominate domestic market (60-70% of China volume) with lower-cost strains (30-50% below Western prices) but often lack clinical evidence (RCTs) for international markets. For freeze-dried powder products with annual production line capacity of approximately 50-150 tons, gross profit margin is generally between 35% and 55%. Key quality attributes: viable count (CFU/g), acid/bile resistance, stability (shelf life 18-24 months). B. animalis lactis is often used in multi-strain probiotic formulations (with Lactobacillus, other Bifidobacterium). Synbiotic formulations (probiotic + prebiotic) are growing (FOS, GOS, inulin). Infant formula regulations (EU, China, US) specify minimum viable count at expiry (10⁷-10⁸ CFU/g). Pet probiotics (dog, cat) are fastest-growing segment (+15% CAGR) driven by pet humanization.
4. User Case Study & Policy Drivers
User Case (Q1 2026): Mead Johnson (now Reckitt) – infant formula manufacturer. Enfamil infant formula with B. animalis lactis BB-12. Key performance metrics:
- Clinical study (n=200 infants): reduced colic (crying time -50%), improved stool frequency
- Regulatory compliance: FDA GRAS, EFSA QPS, China NMPA approved
- Market positioning: premium infant formula (+20% price premium)
- Viable count: 10⁷ CFU/g at expiry (24-month shelf life)
- Cost per kg: US$120 (BB-12) – premium justified by clinical evidence and brand reputation
Policy Updates (Last 6 months):
- EFSA – QPS list update (December 2025): B. animalis lactis remains on QPS list (qualified presumption of safety). No additional safety requirements.
- China NMPA – Infant formula regulations (January 2026): Requires strain-level identification, minimum viable count (10⁷ CFU/g at expiry), and clinical evidence for probiotic claims. Domestic strains preferred.
- FDA – GRAS notification (November 2025): B. animalis lactis strains (BB-12, Bi-07) have GRAS status. No further notifications required.
5. Technical Challenges and Future Direction
Despite strong growth, several technical challenges persist:
- Patent barriers: Core strains (BB-12, Bi-07) are patented. Generic strains cannot use patented strain names. New strain development requires significant R&D investment (US$1-5 million).
- Viability during processing: Heat, oxygen, and shear stress during manufacturing (spray drying, tableting) reduce viability. Microencapsulation and freeze-drying technologies improve stability (10-30% higher survival).
- Clinical evidence gap: Many strains lack robust RCTs (randomized controlled trials). Regulatory approval and consumer trust require clinical evidence (US$1-5 million per indication).
独家行业分层视角 (Exclusive Industry Segmentation View):
- Discrete infant formula and clinical applications (premium products) prioritize clinically validated strains (BB-12), high viable count (>10¹⁰ CFU/g), and regulatory compliance (GRAS, QPS, NMPA). Typically use Novonesis, IFF, Lallemand, Probiotical, Sacco, Howaru. Key drivers are clinical evidence and brand reputation.
- Flow process supplements and pet food applications (value products) prioritize cost (US$60-100 per kg), adequate viability (10⁹-10¹⁰ CFU/g), and multi-strain formulations. Typically use Yili, Wecare, Scitop, Glac, Yuansheng, BGI, Yikewei, Innoorigin, ProbioWay, Bio-Growing. Key performance metrics are cost per kg and viable count at expiry.
By 2030, B. animalis lactis strains will evolve toward next-generation probiotics (live biotherapeutic products, LBPs) for specific indications (irritable bowel syndrome, obesity, metabolic syndrome). Spore-forming B. animalis lactis (enhanced stability) and postbiotics (heat-killed, metabolites) are emerging. As gut health probiotic demand grows and infant formula probiotic regulations tighten, B. animalis lactis will remain a leading probiotic strain globally.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
